Trial ID or NCT#



not recruiting iconNOT RECRUITING


Open-label, non-randomized, parallel assignment, phase 2 trial assessing the safety and efficacy of distinct temozolomide treatment regimens for patients with AML and poor prognosis

Official Title

Phase II Study of Two Distinct Tailored Temozolomide Regimens for Patients With Acute Myeloid Leukemia Age > 60 Years and Poor Risk/Refractory Disease

Eligibility Criteria

Ages Eligible for Study: Older than 60 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Jason Gotlib
Hematologist, Medical oncologist, Leukemia specialist
Professor of Medicine (Hematology)
Steven Coutre
James L. Zehnder, M.D.
James L. Zehnder, M.D.
Hematologist, Pathologist
Professor of Pathology (Research) and of Medicine (Hematology)

Contact us to find out if this trial is right for you.


Richa Rajwanshi
(650) 736-4031